

Proposal by the Nomination Committee, EGM 2021

The Nomination Committee has consisted of Peter Lundkvist (chairman), appointed by Tredje AP-fonden (Third Swedish National Pension Fund), Jack Li appointed by Sino Biopharmaceutical; Yan Cheng appointed by Worldwide International Investments Ltd; Hans Möller, appointed by Karolinska Institutet Holding AB and Torgny Wännström, appointed by Insamlingsstiftelsen för främjande och utveckling av medicinsk forskning vid KI.

The Nomination Committee proposes that the Extraordinary General Meeting resolves as follows:

Lawyer Johan Hessius (Cirio Law Firm) is appointed to chair the Extraordinary General Meeting, or in his absence, a person appointed by the Board of Directors.

Anna Lefevre Skjöldebrand and Ben Toogood are elected as new directors of the Board of Directors. Directors Hans Wigzell and Magnus Persson have resigned from their positions.

Björn Cochlovius is elected as new chairman of the Board of Directors.

Anna Lefevre Skjöldebrand is CEO at Swedish Medtech Service AB, which is the industry organization for the medical technology companies in Sweden. She is further chairperson of Sweden Medtech4Health AB and director of Dedicare AB and Swecare. She has a background in law as, inter alia, lawyer at Advokatfirman Delphi and Head of Legal at Swedish Medtech Service AB. Anna has previously also been a director of, inter alia, the e-Health agency, SIS AB and the Board for Public Procurement. She has also been an expert in several working groups in Sweden and the EU. Anna is independent of the Company and its executive management, and independent in relation to the Company's major shareholders.

Ben Toogood is Head Global Business Development at the pharmaceutical company Sino Biopharmaceuticals Limited. He was previously Head Global BD & M&A at Sandoz AG. He has also previous experience as, inter alia, Group New Business Development Executive at Aspen Pharmacare Holdings and Vice President Global Business Development at Pharmathen SA. Ben has an Executive MBA from Cambridge University, a Masters of Science in Medicine Degree from University of the Witwatersrand and a Pharmacy Degree from Rhodes University. Ben is independent of the Company and its executive management. He is not independent in relation to the Company's major shareholders.